UBS Group’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $482K | Buy |
195,327
+77,647
| +66% | +$192K | ﹤0.01% | 4867 |
|
|
2025
Q1 | $234K | Sell |
117,680
-100,506
| -46% | -$200K | ﹤0.01% | 5203 |
|
|
2024
Q4 | $637K | Buy |
218,186
+183,165
| +523% | +$535K | ﹤0.01% | 4542 |
|
|
2024
Q3 | $136K | Buy |
35,021
+12,482
| +55% | +$48.3K | ﹤0.01% | 4962 |
|
|
2024
Q2 | $116K | Sell |
22,539
-19,984
| -47% | -$103K | ﹤0.01% | 4952 |
|
|
2024
Q1 | $298K | Buy |
42,523
+11,111
| +35% | +$77.8K | ﹤0.01% | 4449 |
|
|
2023
Q4 | $278K | Sell |
31,412
-12,360
| -28% | -$110K | ﹤0.01% | 4387 |
|
|
2023
Q3 | $418K | Sell |
43,772
-55,267
| -56% | -$527K | ﹤0.01% | 3732 |
|
|
2023
Q2 | $1.45M | Buy |
99,039
+94,104
| +1,907% | +$1.38M | ﹤0.01% | 2964 |
|
|
2023
Q1 | $60.7K | Buy |
4,935
+3,726
| +308% | +$45.8K | ﹤0.01% | 5225 |
|
|
2022
Q4 | $22.5K | Buy |
+1,209
| New | +$22.5K | ﹤0.01% | 6361 |
|